Logo
ABBV logo
AbbVie Inc.
ABBV
207.94 (-2.10%) 4.37
Health Care
Biotechnology
AbbVie Inc. a research-based biopharmaceutical company engages in the research and development manufacturing commercializing and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables plastics and regenerative medicine body contouring and skincare products; botox Cosmetic for the treatment of glabellar lines crow's feet forehead lines and platysma bands; Juvederm Collection to treat volume loss in the temples undereye cheeks chin lips and lower face; Vraylar to treat schizophrenia bipolar disorder and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations as well as Botox Therapeutic to treat chronic migraine overactive bladder spasticity cervical dystonia and other conditions. In addition the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products including Refresh/Optive Xen Durysta and Restasis. Further it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago Illinois.

Quality Checklist 1/8

Est. EPS Growth > 5%
5Y Shares Out Change < 0%
ROIC > 10%
Debt/Equity < 1
Current Ratio > 1
Quick Ratio > 1
Net Margin > 10%
Past Net Income CAGR > 0%
0.0%of Portfolio

My holdings

Day change:
Total change:
Shares:
Cost basis:
Market cap: $367.80(B)
EV: $408.14(B)
Total Equity: $-3.23(B)
Earnings date: Apr-29-2026
P/E: 87.74
Forward P/E: 14.33
P/FCF: 20.63
P/S: 6.02
P/B: N/A
EPS: $2.4
EPS (fwd): $14.5
FCF/share: $10.1
Revenue/share: $34.6
Book value/share: $-1.9
ROIC: 3.3%
ROA: 1.7%
ROE: 140.9%
Debt/Equity: 48
Current Ratio: 0.70
Gross margin: 71.6%
Operating margin: 24.1%
Net margin: 6.9%
Dividend/share: $6.7
Div. yield: 3.20%
All Valuation Overview Growth Financials & KPIsCompetitors & Peer Comparison Ownership Tools

ABBV Valuation & Price Targets

Current Price
$208

Favorite Valuation Methods

PEvaluation
N/A
Analyst targets
N/A
DCF (2-stage)
N/A

More Valuation Methods

DCF (simple)
N/A
N/A
DCF (exit mult.)
N/A
N/A
DDM
N/A
N/A
EPS growth
N/A
N/A
Revenue growth
N/A
N/A
Peter Lynch FV
N/A
N/A
Graham No.
N/A
N/A

PEvaluation

2% overvalued
Low
$152
Mid
$203
High
$254
Current price
$208
Fair P/E
Margin of safety
EPS
Market Model
ROICRevenue growthFCF MarginShares outstan...Debt/EquityDebt/EBITDA
Economic moat: Wide

EPS Estimates

LowAvgHigh#
FY+114.014.515.331
FY+214.916.117.429
FY+315.617.719.522
FY+416.519.221.315
FY+516.919.721.815

Analyst Price Targets

20% undervalued
Low
$184
Mid
$250
High
$299
Current price
$208

Analyst Recommendations

Strong Buy8
Buy14
Hold9
Sell0
Strong Sell0

2-stage DCF

First Stage Duration: 5 Years
Starting Free Cash Flow
First Stage Growth Rate
LowMidHigh
Terminal Growth Rate
LowMidHigh
Discount Rate

Discounted Cash Flow

Forecast years: 5 Years
Terminal Growth Rate
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Discounted Cash Flow (exit mult.)

Forecast years: 5 Years
Exit FCF Multiple
LowMidHigh
Discount Rate
Free cash flow estimates:
Y+1 est.
Y+2 est.
0.00%
Y+3 est.
0.00%
Y+4 est.
0.00%
Y+5 est.
0.00%

Dividend Discount Model

Annual Dividend
First Stage Length (Years): 0 Years
First Stage Growth Rate
Final Growth Rate
Discount Rate

EPS Growth

Forecast years: 5 Years
Starting EPS
EPS Growth Rate
LowMidHigh
Final P/E
LowMidHigh
Discount Rate

Revenue Growth Valuation

Forecast Years: 10 Years
Base Revenue
Revenue Growth Rate
LowMidHigh
Final Net Margin
LowMidHigh
Final P/E Ratio
LowMidHigh
Discount Rate

Peter Lynch Fair Value

Earnings Per Share
Growth Rate

Graham Formula

Earnings Per Share
EPS Growth (7-10 years)
Government Bond Rate
(C) PEVALUATOR
About
Terms & privacy
Price charts & news courtesy of TradingView
Blog
Contact